Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec:208:170-172.
doi: 10.1016/j.thromres.2021.11.008. Epub 2021 Nov 16.

Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?

Marco Zuin  1 , Carlo Cervellati  2 , Gianluca Rigatelli  3 , Giovanni Zuliani  2 , Loris Roncon  3
Affiliations
Comment

Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?

Marco Zuin et al. Thromb Res. 2021 Dec.
No abstract available

Keywords: COVID-19; IL-6 antagonists; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Forrest plot investigating the risk of venous thromboembolic events in COVID-19 patients treated with IL-6 antagonists or standard of care.
Supplementary file 2
Supplementary file 2
Risk of bias assessment.
Supplementary file 3
Supplementary file 3
Funnel plot for the risk of venous thromboembolic events in COVID-19 patients treated with IL-6 antagonists or standard of care.
See this image and copyright information in PMC

Comment on

References

    1. Vaughn V.M., Yost M., Abshire C., Flanders S.A., Paje D., Grant P., Kaatz S., Kim T., Barnes G.D. Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID-19. JAMA Netw. Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.11788. - DOI - PMC - PubMed
    1. Thachil J., Tang N., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J. Thromb. Haemost. 2020;18(5):1023–1026. doi: 10.1111/jth.14810. - DOI - PMC - PubMed
    1. Eljilany I., Elzouki A.N. D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review. Vasc Health Risk Manag. 2020 Nov 13;16:455–462. doi: 10.2147/VHRM.S280962. - DOI - PMC - PubMed
    1. Giannakodimos I., Gkountana G.V., Lykouras D., Karkoulias K., Tsakas S. The role of Interleukin-6 in the pathogenesis, prognosis and treatment of severe COVID-19. Curr Med Chem. 2020 doi: 10.2174/0929867328666201209100259. Epub ahead of print. - DOI - PubMed
    1. Page M., JAC Sterne, Savović J. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898. - DOI - PubMed